Please ensure Javascript is enabled for purposes of website accessibility

Nephron to produce diagnostic kits in new partnership

Staff Report //July 6, 2020//

Nephron to produce diagnostic kits in new partnership

Staff Report //July 6, 2020//

Listen to this article

A new collaboration with specialty pharmaceuticals company Methapharm will allow Nephron Pharmaceuticals Corp. to produce kits to help diagnose respiratory illnesses.

The kits contain methacholine chloride sterile inhalation solution in ready-to-administer concentrations for bronchoprovocation challenge testing used to diagnose conditions such as asthma, according to a news release.

“Methapharm will be a fantastic partner,” Nephron CEO Lou Kennedy said in the release. “Patients deserve access to the very best respiratory tests available. That’s what this collaboration will offer, and that’s why we are looking forward to working with Methapharm.”

The stable, room-temperature kits use provocholine, the only chloride powder approved by the Food and Drug Administration for use in humans.

“Through this partnership with Nephron, Methapharm continues its mission to help reduce barriers to testing, provide the level of quality our customers expect, and contribute to better healthcare outcomes for our patients,” Methapharm CEO Craig Baxter CEO said. “We’ve been impressed by Nephron’s capabilities and professionalism.”

West Columbia-based Nephron develops and produces generic inhalation solutions and suspension products, including those used to treat respiratory symptoms associated with COVID-19. The company also operates a 503B outsourcing facility division which produces pre-filled sterile syringes and IV bags for U.S. hospitals.

p